> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sandoz Recall Losartan Lot Due to Impurity
- URL: https://www.fdaweb.com/sandoz-recall-losartan-lot-due-to-impurity/
- Published: 2018-11-09T12:00:00.000Z
- Updated: 2026-09-15T00:43:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142787

Sandoz has recalled one lot of losartan potassium and hydrochlorothiazide after an impurity, NDEA (N-nitrosodiethylamine), was detected in the active pharmaceutical ingredient. The impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC), according to a [recall notice](https://www.fda.gov/Safety/Recalls/ucm625492.htm?ref=fdaweb.com). Losartan potassium and hydrochlorothiazide is indicated for treating hypertension.